Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino(University of Parma), Violeta Serra(Vall d'Hebron Institut de Recerca)
Cited by 94
Related Papers
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
|Oncogene|2011|534
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
|Genome Medicine|2024|58
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts
|npj Precision Oncology|2025|0